Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

Authors not listed

Nordic Lymphoma Group · 2021

Abstract

This is a phase II trial, with the aim of developing a chemotherapy-free regimen for untreated patients with mantle cell lymphoma (MCL). Acalabrutinib (ACP-196) is a next generation bruton tyrosine kinase (BTK) inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab. In this trial proposal, we will also assess the activity of this combination in comparison to a historical control of ibrutinib + rituximab, consisting of the experimental arm of ibrutinib + rituximab in the randomized ENRICH trial (EudraCT number 2015-000832-13), and data from our previous trial with R-bendamustine-lenalidomide (NLG-MCL4). The duration of treatment will be a minimum of 12 months. Patients in molecular remission in blood and bone marrow and in complete remission according to CT, will then stop acalabrutinib, but continue on rituximab for a maximum of 36 months. Patients that are minimal residual disease positive (MRD+) will be evaluated again every 6 months and continue on acalabrutinib for a maximum of 36 months. Patients without a molecular marker, that cannot be followed with MRD, will stop treatment if in CR with PET at 12 months, and be followed by PET-CT every 6 months for a maximum of 36 months. Patients who convert back to MRD positive after stopping acalabrutinib are reinstalled on acalabrutinib until progression. Patients with TP53 aberrations and/or blastoid histology, will monitor MRD but continue with treatment until progression regardless of MRD results. A planned interim analysis will be performed when 40 patients have undergone response assessment after 6 months, for futility and efficacy. If less than 16 of 40 patients obtain a CR, the trial will be stopped due to futility.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-06 MST

Cite this

APA
Anonymous. (2021). Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma. <em>Nordic Lymphoma Group</em>. https://clinicaltrials.gov/study/NCT05214183
Vancouver
Anonymous. Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma. Nordic Lymphoma Group. 2021.
BibTeX
@misc{anon2021Acalab, title = {Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma}, author = {Anonymous}, journal = {Nordic Lymphoma Group}, year = {2021}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings